Jeroen Vincent
A5027679532- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Gut microbiota and health
- Oral health in cancer treatment
- Esophageal Cancer Research and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Screening and Detection
- Cancer Treatment and Pharmacology
- Genetic factors in colorectal cancer
- Cancer Research and Treatments
- Enhanced Recovery After Surgery
- Pharmaceutical Practices and Patient Outcomes
- Gallbladder and Bile Duct Disorders
- Neutropenia and Cancer Infections
- Phytoestrogen effects and research
- Dialysis and Renal Disease Management
- Surgical site infection prevention
- Medication Adherence and Compliance
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Advances in Oncology and Radiotherapy
- Glutathione Transferases and Polymorphisms
- Immunotherapy and Immune Responses
- Delphi Technique in Research
- Virus-based gene therapy research
- Lung Cancer Diagnosis and Treatment
Elkerliek Ziekenhuis
2018-2025
Dutch Colorectal Cancer Group
2024
St. Antonius Ziekenhuis
2017
The University of Texas Health Science Center at San Antonio
2014
Maastricht University Medical Centre
2014
Clinique Hartmann
2006
<h3>Importance</h3> The role of primary tumor resection (PTR) in synchronous patients with metastatic colorectal cancer (mCRC) who had unresectable metastases and few or absent symptoms their is unclear. Studying subgroups low postoperative mortality may identify potentially benefit from PTR. <h3>Objective</h3> To determine the difference 60-day between randomized to systemic treatment only vs PTR followed by treatment, explore risk factors associated mortality. <h3>Design, Setting,...
Upfront primary tumor resection (PTR) has been associated with longer overall survival (OS) in patients synchronous unresectable metastatic colorectal cancer (mCRC) retrospective analyses. The aim of the CAIRO4 study was to investigate whether addition upfront PTR systemic therapy resulted a benefit mCRC without severe symptoms their tumor.
This clinical study explored the associations between intestinal microbiota, chemotherapy toxicity, and treatment response in postmenopausal oestrogen receptor positive breast cancer patients.Oestrogen patients were prospectively enroled a multicentre cohort treated with 4 cycles of (neo)adjuvant adriamycin, cyclophosphamide (AC) followed by docetaxel (D). Patients collected faecal sample completed questionnaire before treatment, during AC, D, after completing AC-D. Chemotherapy toxicity...
Previous preclinical and clinical research has investigated the role of intestinal microbiota in carcinogenesis. Growing evidence exists that can influence breast cancer However, needs to be further investigated. This study aimed identify differences between postmenopausal patients controls.This prospective cohort compared richness, diversity, composition histologically proven ER+/HER2- controls. Patients scheduled for (neo)adjuvant adriamycin, cyclophosphamide (AC), docetaxel (D), or...
Tamoxifen is essential in treating estrogen receptor-positive (ER+) breast cancer, primarily through its active metabolite, endoxifen. Emerging research suggests potential interactions between tamoxifen and gut microbiota. This study investigates the effects of on microbiota composition postmenopausal ER+ human epidermal growth factor receptor 2 negative (HER2−) cancer patients explores correlations endoxifen plasma levels. prospective observational included ER+/HER2− patients. Fecal blood...
Metastatic colorectal cancer patients with deficient mismatch repair (dMMR mCRC) benefit from immunotherapy. Interpretation of the single-arm immunotherapy trials is complicated by insignificant survival data during systemic non-immunotherapy. We present on a large, comprehensive cohort dMMR mCRC patients, treated or without non-immunotherapy.Two hundred and eighty-one (n = 54 three prospective Phase 3 CAIRO trials; n 227 Netherlands Cancer Registry). Overall was analysed diagnosis (OS),...
<h3>Importance</h3> Triplet chemotherapy with fluorouracil, folinic acid, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-B) is an effective first-line treatment option for patients metastatic colorectal cancer (mCRC). However, the degree of implementation FOLFOXIRI-B in daily practice unknown. <h3>Objectives</h3> To evaluate current adoption rate mCRC investigate perspectives medical oncologists toward this option. <h3>Design, Setting, Participants</h3> This 1-week, multicenter,...
12515 Background: Advanced ovarian cancer has been included in several studies about an immunotherapy procedure using Autologous Thermostable Hemoderivative Vaccine (ATHV) with anti-progressive tumor effect metastatic malignant disease from different primary tumors (Cancer Biol Ther 2003). Like most vaccines, the net anti-tumoral of ATHV low intensity despite addition adjuvant steps: immune response enhancement by GM-CSF, tolerance break cyclophosphamide or interference CD4+CD25+ regulatory...
Abstract Surgery for esophageal cancer (EC) has been centralized in the Netherlands. However, patients are still diagnosed referral centers and not all discussed with a resection center. The aim of this study was to examine impact implementation regional Upper-GI video multidisciplinary team meeting (MDT) Eindhoven region which should be discussed, on decision-making process, treatment, survival EC. Methods All between 2012 2018 EC, hospitals currently working together Catharina hospital,...